Business Telegraph

.

SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab) Achieved the Primary Endpoint for Rheumatoid Arthritis

  • Written by Telegraph Magazine

HONG KONG SAR - Media OutReach - 26 April 2023 - A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce that Phase III clinical trial of SinoMab's flagship product SM03 (Suciraslimab) for rheumatoid arthritis (RA) in China (Study No.

Read more: SinoMab Announces that Phase III Clinical Trial of its Flagship Product SM03 (Suciraslimab)...

More Articles ...

  1. Organisations in North Asia urged to leverage the power of security automation as security incidents increase
  2. Early Learning's Fun Preschool Reduces Staff Turnover and Boosts Retention Rates
  3. Hong Kong's First Resin Art Exhibition by 90s Artist Rolland Cheung
  4. Undergrads from SP Jain’s Class of 2022 land international jobs
  5. DETERMINANT Spring/ Summer ‘23 Collection
  6. Zuellig Pharma Recognised with A Score Of "A-" On CDP Supplier Engagement In Industry First
  7. KPMG China Holds Launch Events at Five Offices to Mark Release of Our Impact Plan FY2022
  8. Garment Innofacturer® TAL Apparel Receives its First ‘Caring Company" Commendation
  9. Dyson’s global dust study suggests that heightened cleaning schedules are being abandoned as the world reopens after the COVID-19 pandemic
  10. Save the Children Hong Kong Releases Survey Findings on "Public Views on Corporal Punishment on Children"